Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NYrofG9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMECwOFU5KG6P M2\CTHNCVkeHUh?=
ES4 M3Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PlZWlEPTB;MD6wNFA3PTNibl2= NXnyd|B7W0GQR1XS
ACHN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonPTWM2OD1yLkCwNFg5PyCwTR?= Mmr0V2FPT0WU
KYSE-510 NFXTUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTuZ3NKSzVyPUCuNFAxQTd3IH7N NV2zZll7W0GQR1XS
EW-7 NWmxdGh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMECyOVghdk1? Mmm0V2FPT0WU
BFTC-905 NUTvbIQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX0TWM2OD1yLkCwOVE2KG6P MYnTRW5ITVJ?
KE-37 M4O4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe0WJd[UUN3ME2wMlAxPTZzIH7N M4OzXnNCVkeHUh?=
SBC-5 NF\sRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jkb2lEPTB;MD6wNFU4KG6P NEnkbW5USU6JRWK=
NKM-1 NI\YTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LhTWlEPTB;MD6wNFcxQSCwTR?= M1j3b3NCVkeHUh?=
RH-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37mdWlEPTB;MD6wNFcyQCCwTR?= MoHhV2FPT0WU
ALL-PO M4PNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DXVmlEPTB;MD6wNFg{KG6P MWfTRW5ITVJ?
QIMR-WIL NE\XUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEC4PVQhdk1? NV7RWlA{W0GQR1XS
A375 M3TtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC5PVUhdk1? M3LUNnNCVkeHUh?=
SIG-M5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEGwOEBvVQ>? NFrOV3dUSU6JRWK=
KGN NIHEW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PyTmlEPTB;MD6wNVA5KG6P NVPCN3VGW0GQR1XS
EW-13 M2PjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEGxNkBvVQ>? NH:zeXlUSU6JRWK=
NCI-SNU-1 NHjUXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEG2JI5O NWi2XnNLW0GQR1XS
PSN1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLQUVRKSzVyPUCuNFE3PSCwTR?= NXnxVIJWW0GQR1XS
HUTU-80 M1\Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEG2OkBvVQ>? NV3jWo5mW0GQR1XS
EW-16 NHztTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfVNYxKSzVyPUCuNFI{KG6P MljzV2FPT0WU
786-0 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDZNo1FUUN3ME2wMlAzOyCwTR?= M2TPTXNCVkeHUh?=
ES1 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;V[VdbUUN3ME2wMlAzPjhibl2= MW\TRW5ITVJ?
RKO NUDy[4VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v5eGlEPTB;MD6wNlc6KG6P NF:0[llUSU6JRWK=
ESS-1 NWX2OYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfXRmZQUUN3ME2wMlAzQDZibl2= Mn;3V2FPT0WU
SK-UT-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXt[lZNUUN3ME2wMlAzQTdibl2= MXTTRW5ITVJ?
LB2241-RCC M3PIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRdYRnUUN3ME2wMlA{OThibl2= Ml7BV2FPT0WU
CHL-1 NUjuVHFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5RoV2UUN3ME2wMlA{OjRibl2= NEjsVZhUSU6JRWK=
SW1783 NXPU[IUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDZTWM2OD1yLkCzN|Yhdk1? M3\nRnNCVkeHUh?=
MEL-JUSO MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHlTWM2OD1yLkCzPVEhdk1? MX;TRW5ITVJ?
HT-29 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLtbpNtUUN3ME2wMlA1OTNibl2= MUfTRW5ITVJ?
SNG-M NFzBO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3RTWM2OD1yLkC0NlUhdk1? NEfMfGlUSU6JRWK=
TE-15 NV;lV5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP6TWM2OD1yLkC0OlQhdk1? NFW0d2RUSU6JRWK=
HOS NVjLPJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\EZmZGUUN3ME2wMlA1QCCwTR?= NHTBNmdUSU6JRWK=
BB65-RCC NXm5e3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfmXm41UUN3ME2wMlA2OTJibl2= NFiydnFUSU6JRWK=
HCE-4 NWnQS5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLWSGdKSzVyPUCuNFUzQCCwTR?= MmfLV2FPT0WU
MHH-ES-1 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDDRlZKSzVyPUCuNFU{OSCwTR?= NX\sZVBkW0GQR1XS
RPMI-7951 NFjVS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHtdZpKSzVyPUCuNFU1OSCwTR?= NIfTN4NUSU6JRWK=
IST-SL2 NUfCZ|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILTSXpKSzVyPUCuNFU5PCCwTR?= MkLjV2FPT0WU
CMK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEW4OkBvVQ>? M3fyVHNCVkeHUh?=
GR-ST M2ThSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3HeVVKSzVyPUCuNFU6PSCwTR?= Mmr4V2FPT0WU
NALM-6 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP3VWdKSzVyPUCuNFYzOiCwTR?= NVSxbWIzW0GQR1XS
RPMI-6666 NY\SW2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Sb2lEPTB;MD6wOlUzKG6P M1zp[3NCVkeHUh?=
LC-2-ad NID3U|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULFbXB7UUN3ME2wMlA3PTNibl2= NYnhPI1QW0GQR1XS
ARH-77 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfBZlBSUUN3ME2wMlA4OTFibl2= Mor6V2FPT0WU
IST-MEL1 NWjMN4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHYeZdKSzVyPUCuNFczPiCwTR?= MnjJV2FPT0WU
SW1710 NWLSO2cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfEeWZKSzVyPUCuNFc2OSCwTR?= M3T5XHNCVkeHUh?=
DEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:1[ZlOUUN3ME2wMlA5QDdibl2= MVzTRW5ITVJ?
AGS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEmwNkBvVQ>? NYXJdZlIW0GQR1XS
NCI-H2122 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n3d2lEPTB;MD6wPVQ3KG6P MojmV2FPT0WU
HSC-4 NEXGT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrxTWM2OD1yLkGwNkBvVQ>? NGfPOmdUSU6JRWK=
AM-38 M2npVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjWXldKSzVyPUCuNVIyKG6P M1G4SnNCVkeHUh?=
769-P MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofUTWM2OD1yLkGyN{BvVQ>? MmGxV2FPT0WU
RT-112 NFXidHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMUK3JI5O NGDNV41USU6JRWK=
MCF7 M3nDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LremlEPTB;MD6xN|Yhdk1? MVXTRW5ITVJ?
IGROV-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzDTWM2OD1yLkG0OUBvVQ>? NWTaNGc{W0GQR1XS
OCI-AML2 NHK1VIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fQU2lEPTB;MD6xOFchdk1? NHLQc4lUSU6JRWK=
NCI-H1299 NULPO45VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzaTWM2OD1yLkG1O{BvVQ>? NYmxWIxXW0GQR1XS
A431 NELpbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH3b|gyUUN3ME2wMlE5OyCwTR?= Mlf1V2FPT0WU
SW982 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPXc3lKSzVyPUCuNlE{KG6P MnvTV2FPT0WU
BB30-HNC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\JRY17UUN3ME2wMlI{OSCwTR?= MYjTRW5ITVJ?
ACN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWftcpl3UUN3ME2wMlI1PCCwTR?= NILZe2lUSU6JRWK=
647-V NFzrNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT4OldoUUN3ME2wMlI1QCCwTR?= NYfKTogzW0GQR1XS
SK-PN-DW MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfBTWM2OD1yLkK2OkBvVQ>? MV\TRW5ITVJ?
LCLC-97TM1 NGWwW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMk[3JI5O Moq5V2FPT0WU
LB1047-RCC NU\KSGNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni4TWM2OD1yLkK2PUBvVQ>? NIm5VpJUSU6JRWK=
A2780 M{G0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMkegcm0> NXrFcW1qW0GQR1XS
C-33-A MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HocGlEPTB;MD6yO|Mhdk1? MlrFV2FPT0WU
NCI-H2228 NIP6[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DmdWlEPTB;MD6zNVQhdk1? MmDiV2FPT0WU
TE-5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\iN2lEPTB;MD6zNVYhdk1? MmK3V2FPT0WU
HC-1 NIC1dlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBTWM2OD1yLkOyO{BvVQ>? NVjHfZdtW0GQR1XS
SK-MES-1 NVrSVmI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm4SmVpUUN3ME2wMlMzQCCwTR?= NGGxWlFUSU6JRWK=
NCI-H1355 NFXFVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwM{ixJI5O MUPTRW5ITVJ?
YKG-1 M2fYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6[Yt{UUN3ME2wMlQyQSCwTR?= NFPsboVUSU6JRWK=
RS4-11 NWLvWW1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNEOzJI5O MXfTRW5ITVJ?
Daoy NIDYVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfJWGh7UUN3ME2wMlQ2PiCwTR?= MlLLV2FPT0WU
A3-KAW NHPk[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwNUWxJI5O M4HIc3NCVkeHUh?=
SK-MEL-30 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXywNYoyUUN3ME2wMlU2PCCwTR?= NIDFO2ZUSU6JRWK=
U031 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHuTWM2OD1yLkW2OUBvVQ>? NGjwTYtUSU6JRWK=
SK-LMS-1 NXrD[JRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HuSWlEPTB;MD61O|ghdk1? NHjmeYNUSU6JRWK=
ES6 NVjHe2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDUTWM2OD1yLkW4OkBvVQ>? NWLITYdIW0GQR1XS
EoL-1-cell NVXpNIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;FcFZYUUN3ME2wMlYyPiCwTR?= MmG3V2FPT0WU
NCI-H2009 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7aTWM2OD1yLk[xPUBvVQ>? NG\rV5pUSU6JRWK=
A4-Fuk Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qZmxmUUN3ME2wMlYzPiCwTR?= M{L6fHNCVkeHUh?=
KYSE-270 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:xdopKSzVyPUCuOlM1KG6P NIjyOGFUSU6JRWK=
SK-LU-1 NUfGb5l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XRZ2lEPTB;MD62OVUhdk1? M1izb3NCVkeHUh?=
SW872 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O0fGlEPTB;MD63OlUhdk1? M1qyfnNCVkeHUh?=
ES8 NXTqXXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjDXVNKSzVyPUCuO|ghdk1? MlT0V2FPT0WU
G-402 NWTTPVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPDTWM2OD1yLke4OEBvVQ>? NHPES3RUSU6JRWK=
ATN-1 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqwTWM2OD1yLkiwO{BvVQ>? MmjWV2FPT0WU
DoTc2-4510 NH3yU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnlXYRKSzVyPUCuPVAyKG6P Mm\aV2FPT0WU
MES-SA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\BTIVKSzVyPUCuPVA2KG6P Mln6V2FPT0WU
SF268 NVvuelJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jiNmlEPTB;MD65Nlchdk1? MV7TRW5ITVJ?
SF539 M1KzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjFeWNKSzVyPUGuNFIhdk1? MlPZV2FPT0WU
NB69 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMEWgcm0> NXyzO|JLW0GQR1XS
8505C Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\he2lEPTB;MT6wOkBvVQ>? NEnIe|dUSU6JRWK=
CAL-12T MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3OTWM2OD1zLkC4JI5O MYLTRW5ITVJ?
BHY MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDMTWM2OD1zLkG0JI5O NHjCU29USU6JRWK=
LB647-SCLC M1nNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rrWWlEPTB;MT6xPEBvVQ>? M{Oyd3NCVkeHUh?=
CAL-62 M{n6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHzOHRKSzVyPUGuNlIhdk1? MkCxV2FPT0WU
MEG-01 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j1VWlEPTB;MT6yO{BvVQ>? NF3mR5BUSU6JRWK=
MG-63 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPN[GZGUUN3ME2xMlM{KG6P NV;OeHdIW0GQR1XS
SW620 NVi0WWliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DlWWlEPTB;MT6zOUBvVQ>? NUPHfmlYW0GQR1XS
A388 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPCTWM2OD1zLkO2JI5O MoXoV2FPT0WU
BCPAP M3O3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4WYYxUUN3ME2xMlQ2KG6P MULTRW5ITVJ?
P30-OHK MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDMTWM2OD1zLkS2JI5O MUfTRW5ITVJ?
Ca9-22 M2PkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTiTWM2OD1zLkW0JI5O M4G4NHNCVkeHUh?=
VMRC-RCZ M323fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNUSgcm0> MYTTRW5ITVJ?
LOXIMVI M3XSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1THZ2lEPTB;MT62JI5O MV\TRW5ITVJ?
L-540 M1nTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH31WllKSzVyPUGuOkBvVQ>? M3\kTXNCVkeHUh?=
NTERA-S-cl-D1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\HNG5YUUN3ME2xMlY1KG6P M2OzbnNCVkeHUh?=
MFH-ino NVftOGg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jEcWlEPTB;MT62OkBvVQ>? M3z5[nNCVkeHUh?=
Calu-6 NYXXTpM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qxNmlEPTB;MT63N{BvVQ>? MXHTRW5ITVJ?
HEL NGHuRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwN{mgcm0> MVLTRW5ITVJ?
CAL-33 NFzwPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\qO2lEPTB;MT64PUBvVQ>? MYrTRW5ITVJ?
HSC-3 M2PHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLGTWM2OD1zLkmxJI5O NFnOXZBUSU6JRWK=
KU812 M3HPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHqb|FKSzVyPUGuPVEhdk1? MWXTRW5ITVJ?
EB2 NGjGcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrHeoVOUUN3ME2yMlAyKG6P NFLQZ5NUSU6JRWK=
SR NH72Zm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLyTWM2OD1{LkGyJI5O M1v4ZXNCVkeHUh?=
NCI-H2087 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XWfWlEPTB;Mj6xOEBvVQ>? MnrTV2FPT0WU
H4 M1vTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\mTWM2OD1{LkG4JI5O NUnMWFFlW0GQR1XS
EW-1 NHf6dXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WUppKSzVyPUKuNlIhdk1? NYnLfXlRW0GQR1XS
MC-IXC M1jCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nlcmlEPTB;Mj6yOkBvVQ>? MUfTRW5ITVJ?
NCI-H727 NEjvZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDTI5KSzVyPUKuOVEhdk1? M2KzZXNCVkeHUh?=
MRK-nu-1 NFLTZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSxTWM2OD1{LkW3JI5O MXLTRW5ITVJ?
COLO-668 NHi1dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwNk[gcm0> MYXTRW5ITVJ?
CGTH-W-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7aSVdKSzVyPUKuO|Ihdk1? NYjZZXdXW0GQR1XS
CHP-212 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7NcndlUUN3ME2yMlc2KG6P MlXpV2FPT0WU
GI-1 NUnhOlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\YfY1wUUN3ME2yMlc3KG6P NHfLbFVUSU6JRWK=
HCC1806 NHvnS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC3ZZdKSzVyPUKuPVEhdk1? NITwcGpUSU6JRWK=
HLE M3\CRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDnU5RKSzVyPUOgcm0> NIDWZmxUSU6JRWK=
HSC-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknvTWM2OD1|LkCzJI5O NUXQfJN1W0GQR1XS
DMS-273 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHhWFRLUUN3ME2zMlA4KG6P NYrxdWNqW0GQR1XS
DU-4475 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWyPI5mUUN3ME2zMlE1KG6P MknuV2FPT0WU
LXF-289 NXvheYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInySphKSzVyPUOuN|Ehdk1? NEHsUGxUSU6JRWK=
PANC-03-27 NWTad3dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\P[mlKSzVyPUOuOVEhdk1? M1PC[3NCVkeHUh?=
GAMG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\NO2c2UUN3ME2zMlc1KG6P M2TNVHNCVkeHUh?=
NCI-H522 MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu5cFZpUUN3ME20MlM1KG6P MXnTRW5ITVJ?
SW626 M4DPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T1VGlEPTB;ND60OkBvVQ>? MVrTRW5ITVJ?
HT-144 M2HWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\pTWM2OD12LkmyJI5O Mon3V2FPT0WU
MEL-HO Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwMU[gcm0> NYDvXJozW0GQR1XS
BE-13 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnkTZlKSzVyPUWuNlEhdk1? MVLTRW5ITVJ?
VA-ES-BJ NE[0fIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfESmVKSzVyPUWuNlYhdk1? M4npeHNCVkeHUh?=
NCI-H441 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPtTWM2OD13Lk[gcm0> NUDGVVlOW0GQR1XS
KP-4 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHntfIVKSzVyPUWuOlEhdk1? NUHTTXpVW0GQR1XS
LoVo M3zTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH3WJBKSzVyPUWuO|Ehdk1? MV;TRW5ITVJ?
HT-1080 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPmZ29nUUN3ME21Mlg{KG6P NWrmW|BbW0GQR1XS
GB-1 M2PwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLETWM2OD13Lki0JI5O MnHlV2FPT0WU
IA-LM NWjkN3l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nlbWlEPTB;NT65NUBvVQ>? MXPTRW5ITVJ?
8-MG-BA M3nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD13LkmzJI5O MVfTRW5ITVJ?
SK-HEP-1 NUTFVmVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZwMUSgcm0> MXXTRW5ITVJ?
697 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PtNWlEPTB;Nj6yOUBvVQ>? NVHMS5d5W0GQR1XS
KYSE-450 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXKeoZLUUN3ME22MlMzKG6P MWTTRW5ITVJ?
HCC2998 M1nqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHicZNKSzVyPU[uN|Qhdk1? NEDKO2hUSU6JRWK=
HD-MY-Z MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7aTWM2OD14Lk[4JI5O M1rqTHNCVkeHUh?=
OS-RC-2 M{e0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfBeI9wUUN3ME22MlY5KG6P NUHDdph5W0GQR1XS
SF126 NIX0folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fIS2lEPTB;Nz6wOUBvVQ>? Mmj2V2FPT0WU
Ca-Ski NEjCW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;RWnBKSzVyPUeuNFkhdk1? NHzxTm9USU6JRWK=
NCI-H358 M3\hNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTdwMU[gcm0> MX3TRW5ITVJ?
J82 NX\QXFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTdwNEGgcm0> NUPEcpluW0GQR1XS
NCI-H2342 NEP1TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjUYpKSzVyPUeuOlMhdk1? NILCZZJUSU6JRWK=
OVCAR-8 NULNc|F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfsWlRKUUN3ME23Mlkhdk1? MUjTRW5ITVJ?
TE-8 NV3EfG9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRThibl2= MkHZV2FPT0WU
ETK-1 NU\kcGVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf3eFVKSzVyPUiuNFghdk1? Moq3V2FPT0WU
HAL-01 NGfZZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ZXWpJUUN3ME24MlIhdk1? M3n3[HNCVkeHUh?=
KYSE-150 M1nMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;4[2lEPTB;OD60O{BvVQ>? M4S0cHNCVkeHUh?=
NCI-H810 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwNU[gcm0> NHT1bFZUSU6JRWK=
ONS-76 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\JTWM2OD16Lk[4JI5O M2j1V3NCVkeHUh?=
NMC-G1 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYiyWZNtUUN3ME24Mlc3KG6P NGXhPIlUSU6JRWK=
C3A M4LyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LnNWlEPTB;OD64OEBvVQ>? M1rRTXNCVkeHUh?=
PA-1 M{jlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKTWM2OD16Lkm5JI5O NVjlRmx{W0GQR1XS
SH-4 NX7Ye2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DaU2lEPTB;OT6wNkBvVQ>? M4XHW3NCVkeHUh?=
EFO-27 M4jwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33jV2lEPTB;OT6wOUBvVQ>? NHjjTZJUSU6JRWK=
CAPAN-1 NXPteopLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTlwMkOgcm0> NV22dGFqW0GQR1XS
DU-145 M{j3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TzRmlEPTB;OT6yPUBvVQ>? MWjTRW5ITVJ?
A101D MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0UW1KSzVyPUmuN|chdk1? NHqwd3NUSU6JRWK=
ST486 NWO4XHBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPOU2pKSzVyPUmuOFEhdk1? Mk\mV2FPT0WU
NCI-H1437 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfKb|BCUUN3ME25MlQzKG6P Mli3V2FPT0WU
HGC-27 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPOfmxKSzVyPUmuOkBvVQ>? NFvnVZpUSU6JRWK=
8305C MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnyWI9JUUN3ME25MlY1KG6P MVfTRW5ITVJ?
OCUB-M NGrpN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[yOWlEPTB;MUCuNFMhdk1? NXrN[29OW0GQR1XS
COLO-679 NEDLUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPmTWM2OD1zMD6wO{BvVQ>? M3q4[nNCVkeHUh?=
Detroit562 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDlTWM2OD1zMD60NkBvVQ>? NEfp[YRUSU6JRWK=
A204 NFryVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFzLkG2JI5O NUG1bJZCW0GQR1XS
NCI-H1734 M3Pxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnXOmxKSzVyPUGxMlI6KG6P MlyyV2FPT0WU
MC-CAR M1HqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfuSmRKSzVyPUGxMlU5KG6P NVLLfYh7W0GQR1XS
NCI-H2170 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvtTWM2OD1zMT65O{BvVQ>? M{G0N3NCVkeHUh?=
NCI-SNU-5 NWCwWnNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP6TWM2OD1zMj6xN{BvVQ>? NWPqem1mW0GQR1XS
HCE-T NI\Ze|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;WN3JKSzVyPUGyMlQzKG6P MmS1V2FPT0WU
KYSE-180 NUn6OFM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF{LkixJI5O NYX5RXFmW0GQR1XS
C8166 NWLnb|ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3YSm1QUUN3ME2xN{4xQCCwTR?= NHzIb3BUSU6JRWK=
NCI-H460 NU\pVmhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn6TWM2OD1zMz61OEBvVQ>? NXTFVII3W0GQR1XS
SNU-449 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jPNWlEPTB;MUOuO|chdk1? NGHnepVUSU6JRWK=
MDA-MB-468 NF7RRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF2LkGyJI5O NE\Pc5JUSU6JRWK=
COR-L23 NXXmOHlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fleGlEPTB;MUSuNVMhdk1? NIjuUmVUSU6JRWK=
CTV-1 NVXSOZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXROXdKSzVyPUG0MlE1KG6P M3i1UnNCVkeHUh?=
BL-41 NYPqRo9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnFTHhKSzVyPUG0MlM4KG6P MYDTRW5ITVJ?
IGR-1 M1:1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfZTWM2OD1zND60NkBvVQ>? NFLxRlBUSU6JRWK=
TK10 NHS4UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF2LkS5JI5O NWHhO3hpW0GQR1XS
REH NHP1[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OzdmlEPTB;MUSuOVEhdk1? Mn3YV2FPT0WU
LU-139 M2naemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF2LkW5JI5O M{Wzd3NCVkeHUh?=
KP-N-YS NU[4S5ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF2Lkm3JI5O NWSzfVI6W0GQR1XS
PANC-10-05 NIHwfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjze2dEUUN3ME2xOU4{QCCwTR?= M33wWXNCVkeHUh?=
HL-60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPUcoRKSzVyPUG1MlY6KG6P M{exNnNCVkeHUh?=
T84 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX75TXF7UUN3ME2xOU46PiCwTR?= MUDTRW5ITVJ?
RPMI-8226 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF4LkCyJI5O MYrTRW5ITVJ?
UM-UC-3 MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vSNWlEPTB;MU[uNVYhdk1? MWfTRW5ITVJ?
TE-10 NE\vVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHLTWM2OD1zNj6yNUBvVQ>? M1HDW3NCVkeHUh?=
CAL-148 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2[GVwUUN3ME2xO{4zOyCwTR?= MVrTRW5ITVJ?
BV-173 NWLhXoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TFWmlEPTB;MUeuNlchdk1? MWDTRW5ITVJ?
Calu-3 NGD5[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PxTGlEPTB;MUeuNlkhdk1? NF;o[HZUSU6JRWK=
RPMI-2650 NES2cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRWJhKSzVyPUG3MlU6KG6P MUPTRW5ITVJ?
MKN45 NV7WOo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPZcXQ4UUN3ME2xO{44OyCwTR?= NU\iboZZW0GQR1XS
NUGC-3 NV3zVY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnkd3A6UUN3ME2xPE4{PCCwTR?= Ml24V2FPT0WU
NCI-H520 NHrrc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF6Lke3JI5O MoPtV2FPT0WU
CCRF-CEM MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LBSWlEPTB;MUiuPFUhdk1? NIC1emtUSU6JRWK=
NCI-H2405 NGXoOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF7LkGgcm0> MWPTRW5ITVJ?
ES7 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nwcmlEPTB;MUmuO|Yhdk1? MVXTRW5ITVJ?
BPH-1 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M372R2lEPTB;MkCuNlghdk1? NITUbHVUSU6JRWK=
SAS NU\0ToxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXjVJVqUUN3ME2yNE42KG6P Mmn6V2FPT0WU
HuCCT1 M2SwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTGU4xKSzVyPUKwMlU5KG6P M1\zbXNCVkeHUh?=
LOUCY MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJyLk[2JI5O MVfTRW5ITVJ?
NCI-H292 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme3TWM2OD1{MD63PUBvVQ>? NXjyVm5SW0GQR1XS
G-361 M2DMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJzLkC3JI5O NV7ZOHpNW0GQR1XS
M059J MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7l[FRKSzVyPUKxMlA5KG6P NInQbHVUSU6JRWK=
NCI-H1651 M4jwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\1TWM2OD1{MT6xNUBvVQ>? NHyyNVdUSU6JRWK=
KALS-1 NYrXPFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3TTWM2OD1{MT6zPUBvVQ>? MUnTRW5ITVJ?
DJM-1 M2nCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWwT2JwUUN3ME2yNU42QSCwTR?= NEP3NFRUSU6JRWK=
AU565 M3HYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJzLkizJI5O M3LZZnNCVkeHUh?=
HCC38 NWra[mhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M133S2lEPTB;MkGuPVUhdk1? NWfjdmt3W0GQR1XS
U251 NFrPdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vTe2lEPTB;MkKuNlchdk1? MULTRW5ITVJ?
ABC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Oye2lEPTB;MkKuOlUhdk1? MlHIV2FPT0WU
SK-NEP-1 NY\TfVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KySWlEPTB;MkKuPVMhdk1? NVjGSW1[W0GQR1XS
CESS Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJ|LkG5JI5O M4TVd3NCVkeHUh?=
MIA-PaCa-2 NIW2e4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHzfHRKSzVyPUKzMlM3KG6P NFTL[IdUSU6JRWK=
SUP-T1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULqRZZpUUN3ME2yN{41PyCwTR?= M4qzNnNCVkeHUh?=
L-428 NFyyfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jvOmlEPTB;MkOuOlIhdk1? MojSV2FPT0WU
SW954 NWnGRoRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ|Lk[4JI5O Mn\tV2FPT0WU
HO-1-N-1 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\4S2lEPTB;MkOuO|chdk1? NYDSVopMW0GQR1XS
CHP-126 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPsZYNKSzVyPUK0MlE1KG6P MlT3V2FPT0WU
HMV-II M3nTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rFSWlEPTB;MkSuN|Qhdk1? MoGxV2FPT0WU
NB10 M4PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKz[nVKSzVyPUK0MlM4KG6P M2r3cXNCVkeHUh?=
A172 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\TeFJKSzVyPUK0MlcyKG6P MlX0V2FPT0WU
MONO-MAC-6 M4G0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLH[4xbUUN3ME2yOE45PCCwTR?= M3PHcXNCVkeHUh?=
NCI-H1650 NFvHRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvaTWM2OD1{NT60JI5O M4nESXNCVkeHUh?=
NH-12 M{H0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ3LkWgcm0> NF;qSIpUSU6JRWK=
ML-2 NFPIU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW0PVRmUUN3ME2yOU44PCCwTR?= MYPTRW5ITVJ?
MZ2-MEL NUjueWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD1{Nj6yNkBvVQ>? MUXTRW5ITVJ?
COLO-684 NX;rb3R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPvVpRXUUN3ME2yOk41OSCwTR?= MYLTRW5ITVJ?
HuP-T4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ5LkOgcm0> MoDGV2FPT0WU
SW837 NITtbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDqV|VKSzVyPUK3MlYzKG6P NH3ifVBUSU6JRWK=
MDA-MB-231 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3tSnRLUUN3ME2yO{44QCCwTR?= M2SzS3NCVkeHUh?=
KYSE-140 M{XqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\wbIdKSzVyPUK3MlkyKG6P NHvwTmdUSU6JRWK=
NOMO-1 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ6Lk[4JI5O MmLXV2FPT0WU
GP5d NWm5SpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonsTWM2OD1{OD63NkBvVQ>? M{K5NnNCVkeHUh?=
COR-L105 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnOdHpKSzVyPUK5MlQzKG6P MVzTRW5ITVJ?
LS-411N MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\aVWlEPTB;MkmuPFghdk1? MXTTRW5ITVJ?
NY MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:yTWM2OD1|MD6xPEBvVQ>? MlXvV2FPT0WU
NCI-H2030 NYfj[m5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTNyLkS1JI5O NGnOOJpUSU6JRWK=
CCF-STTG1 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnyTWM2OD1|MT60NkBvVQ>? Mk\jV2FPT0WU
NCI-H1703 NXj6XHBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNzLke4JI5O MXTTRW5ITVJ?
TUR NIXQdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfWWWdbUUN3ME2zNk4xOyCwTR?= NGHTOo1USU6JRWK=
NOS-1 NIqzRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3UGlEPTB;M{KuOFQhdk1? MWLTRW5ITVJ?
A2058 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvPTWM2OD1|Mj64N{BvVQ>? NVXrVWtYW0GQR1XS
LCLC-103H MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG3TWM2OD1|Mz6yOUBvVQ>? M3nmfnNCVkeHUh?=
NCI-H510A MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPlNpVKSzVyPUOzMlI4KG6P NUPZemROW0GQR1XS
BC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;4V|ZkUUN3ME2zN{44PyCwTR?= MYPTRW5ITVJ?
SK-CO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fDfWlEPTB;M{SuNFEhdk1? MV;TRW5ITVJ?
A673 M1PkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN2LkG3JI5O NYrIXJJwW0GQR1XS
VM-CUB-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTN2Lk[5JI5O MnezV2FPT0WU
HH M1zNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD1|NT6wOkBvVQ>? M{XvenNCVkeHUh?=
CAL-27 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K2TWlEPTB;M{WuNVYhdk1? NVvMWpd4W0GQR1XS
NEC8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrsTmo2UUN3ME2zOU4{PyCwTR?= MWPTRW5ITVJ?
BxPC-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XBN2lEPTB;M{[uPVEhdk1? MWXTRW5ITVJ?
SNB75 NHXnWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN5LkK0JI5O M2\FOnNCVkeHUh?=
NB13 M2TWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXnTWM2OD1|OD6yN{BvVQ>? M4PUfHNCVkeHUh?=
SK-OV-3 NWrDO3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjScoJlUUN3ME2zPE44PCCwTR?= MnLSV2FPT0WU
ME-180 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN6Lkigcm0> M4\Uc3NCVkeHUh?=
JiyoyeP-2003 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fHfGlEPTB;M{muN|ghdk1? MXfTRW5ITVJ?
LU-134-A NFTLU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrBTWM2OD12MD6wNkBvVQ>? Mn3kV2FPT0WU
LS-123 NHzYc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTRyLkK4JI5O MUPTRW5ITVJ?
COLO-800 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZW|lwUUN3ME20NE42PiCwTR?= M13IRnNCVkeHUh?=
LB831-BLC M2LHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3uTWM2OD12MT64OUBvVQ>? MXfTRW5ITVJ?
NCI-H747 NH3rd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXJTWR5UUN3ME20Nk4zQCCwTR?= MXHTRW5ITVJ?
MZ7-mel NXfzWohQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR{Lk[2JI5O MWrTRW5ITVJ?
GT3TKB M3j0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rrcmlEPTB;NEKuO|Ihdk1? NFTYdnJUSU6JRWK=
MOLT-16 M2L6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTQTWM2OD12Mz6wOUBvVQ>? M322RnNCVkeHUh?=
23132-87 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr2NI1KSzVyPUSzMlA2KG6P M{\se3NCVkeHUh?=
PF-382 M4DrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;xXYJKSzVyPUS0MlIzKG6P Ml3qV2FPT0WU
ES3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljCTWM2OD12ND62JI5O NXjMZ5NvW0GQR1XS
SW756 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR3LkG0JI5O MX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03865563 Not yet recruiting Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California San Diego July 2019 Phase 2
NCT03865563 Not yet recruiting Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California San Diego July 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID